» Articles » PMID: 27778323

The Incidence and Mortality Rates of Neuroblastoma Cases Before and After the Cessation of the Mass Screening Program in Japan: A Descriptive Study

Overview
Journal Int J Cancer
Specialty Oncology
Date 2016 Oct 26
PMID 27778323
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

In 2003, Japan's Ministry of Health, Labour and Welfare halted the neuroblastoma (NB) mass screening program, running since 1985. This study aimed to examine whether NB incidence and mortality changed before and after the program halted. This is a descriptive population-based study. We used data from the Monitoring of Cancer Incidence in Japan (MCIJ) project, Vital Statistics of Japan, and Japanese CANcer Survival Information for Society (J-CANSIS). Incidence rate, cumulative incidence rate, mortality rate, cumulative mortality rate, and relative 5-year survival for NB were calculated. Children were divided into two birth cohort groups, consisting of children born before, or after the cessation of the NB mass screening program. We compared the two cohorts, with regards to the cumulative incidence and mortality rates at 5 years old. The incidence rate was lower after the cessation of the NB mass screening program. There was no substantial change in the mortality rate, and no significant variation in the relative 5-year survival between groups. The cumulative incidence rate in the latter cohort was significantly lower than that in the former cohort (rate ratio: 0.39, 95% CI: 0.25-0.61, p < 0.001). No significant difference in the cumulative mortality rate between the two cohorts was observed (rate ratio: 0.99, 95% CI: 0.80-1.22, p = 0.93). The NB incidence rate decreased markedly and the mortality rate did not substantially change after the cessation of the NB mass screening program. The NB mass screening program probably caused overdiagnosis, and its effectiveness was not clear.

Citing Articles

BAP31 Promotes Angiogenesis via Galectin-3 Upregulation in Neuroblastoma.

Namusamba M, Wu Y, Yang J, Zhang Q, Wang C, Wang T Int J Mol Sci. 2024; 25(5).

PMID: 38474195 PMC: 10931962. DOI: 10.3390/ijms25052946.


A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019.

Campbell K, Siegel D, Umaretiya P, Dai S, Heczey A, Lupo P Pediatr Blood Cancer. 2023; 71(1):e30732.

PMID: 37867409 PMC: 11018254. DOI: 10.1002/pbc.30732.


The burden of childhood and adolescent cancers in North Africa and the Middle East (NAME) region: findings from the Global Burden of Disease study 2019.

Karimi A, Moghaddam S, Azadnajafabad S, Esfahani Z, Tehrani Y, Abbasi-Kangevari M BMC Pediatr. 2023; 23(1):113.

PMID: 36890483 PMC: 9992906. DOI: 10.1186/s12887-023-03931-4.


Cancer overdiagnosis: a challenge in the era of screening.

Dunn B, Woloshin S, Xie H, Kramer B J Natl Cancer Cent. 2022; 2(4):235-242.

PMID: 36568283 PMC: 9784987. DOI: 10.1016/j.jncc.2022.08.005.


Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.

Berthold F, Spix C, Erttmann R, Hero B, Michaelis J, Treuner J JNCI Cancer Spectr. 2021; 5(4).

PMID: 34240006 PMC: 8259619. DOI: 10.1093/jncics/pkab041.